TrumpRx: A Discount Mirage? Drug Prices Still Higher Than UK for Many
President Trump’s initiative, TrumpRx.gov, aimed to deliver the lowest prescription drug prices globally. However, a recent Reuters analysis reveals a mixed bag. While some medications, particularly weight-loss and fertility drugs, are seeing significant discounts, prices for roughly a third of the drugs listed on the site remain higher than those paid in the United Kingdom.
The Promise vs. Reality of Most Favored Nation Pricing
Launched in January, TrumpRx operates on the principle of “most favored nation” deals with 16 drugmakers. The goal was to secure prices at or below those charged in other developed nations. The UK, having agreed to increased spending on medicines, became a key benchmark. But the reality is proving more complex.
Drugs like Pfizer’s Xeljanz, AstraZeneca’s Farxiga, and GSK’s inhalers for lung diseases are notably more expensive on TrumpRx than in the UK – with price differences ranging from 67% to 82%. This discrepancy casts doubt on President Trump’s claims of slashing U.S. Drug prices to the “lowest” worldwide, and refutes his assertion that some medicines are now “300% to 600%” cheaper, a claim described as mathematically impossible.
Where TrumpRx *Is* Delivering Savings
Despite the shortcomings, TrumpRx is offering substantial savings on certain medications. The most significant discounts are currently found in the market for obesity drugs, specifically Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Both companies agreed to cut prices to between $149 and $350 a month, down from over $1000 previously.
Fertility drugs are also experiencing price cuts, with EMD Serono offering an 84% discount from list prices on its three U.S. Fertility drugs. These savings are particularly important as these medications are often not covered by insurance.
The Role of Cash Prices and Insurance
Experts emphasize that TrumpRx primarily reflects direct-to-consumer cash prices, rather than the prices most Americans pay through private or government-sponsored insurance. Wayne Winegarden, a medical economist, describes TrumpRx as “a big… really expensive coupon book,” offering discounts for those paying out-of-pocket.
The UK’s National Health Service (NHS), in contrast, negotiates prices directly with pharmaceutical companies and offers prescriptions at a standard charge of £9.90 (approximately $13.19) per medicine, or free in Scotland, Wales, and Northern Ireland. Americans with insurance typically pay a flat-fee copay or coinsurance based on their plan.
Impact on Drugmakers: A Mixed Bag
The impact of TrumpRx on drugmaker profits is varied. Swiss companies Novartis and Roche anticipate minimal impact, while Novo Nordisk has warned of potential sales and profit declines of up to 13% in 2026. Johnson & Johnson estimates its losses will be in the “hundreds of millions of dollars,” though BMO Capital Markets analyst Evan Seigerman notes Here’s a small percentage of their overall pharmaceutical sales.
The effect appears to be more pronounced for companies with a larger share of sales coming through government-sponsored programs.
The Future of Drug Pricing: What’s Next?
The TrumpRx experiment highlights the complexities of drug pricing and the challenges of achieving substantial, across-the-board savings. The voluntary nature of the program, with no enforcement mechanisms, raises questions about its long-term effectiveness. Harvard Medical School professor Aaron Kesselheim argues that TrumpRx doesn’t address the underlying policy issues driving high drug prices.
Looking ahead, several trends could shape the future of drug pricing:
- Increased State-Level Initiatives: States may take a more active role in negotiating drug prices, potentially following the lead of California and other states exploring bulk purchasing and price transparency measures.
- Biosimilar Competition: The increased availability of biosimilars – lower-cost versions of biologic drugs – could drive down prices in key therapeutic areas.
- Continued Focus on Value-Based Pricing: Payers may increasingly demand value-based pricing agreements, tying drug prices to their clinical outcomes and real-world effectiveness.
- Direct-to-Consumer Models: More drugmakers may explore direct-to-consumer sales models, similar to TrumpRx, but with potentially more robust offerings and broader participation.
The ongoing negotiations between pharmacies, prescription drug savings sites like GoodRx, and the Trump administration suggest a potential expansion of TrumpRx beyond direct sales from manufacturers. This could involve incorporating discount vouchers and leveraging the existing infrastructure of retail pharmacies.
FAQ
Q: Is TrumpRx cheaper than buying drugs in the UK?
A: Not always. A Reuters analysis found that prices for about a third of the drugs on TrumpRx are higher than in the UK.
Q: Who benefits most from TrumpRx?
A: Currently, those paying cash prices for certain medications, particularly weight-loss and fertility drugs, are seeing the biggest savings.
Q: Is TrumpRx mandatory for drugmakers?
A: No, participation is voluntary.
Q: Will TrumpRx lower drug prices for people with insurance?
A: It’s unlikely to have a significant impact for most people with insurance, as it focuses on cash prices.
Did you grasp? The UK’s NHS negotiates drug prices directly with pharmaceutical companies, resulting in significantly lower costs for patients.
Pro Tip: Always compare prices at different pharmacies and explore prescription savings programs like GoodRx, even with TrumpRx available.
What are your thoughts on TrumpRx? Share your experiences and opinions in the comments below. Explore our other articles on healthcare affordability for more insights.
